PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K Filing
Pacific Biosciences reported Q1 2026 revenue of $37.2 million, with consumable revenue rising to $21.8 million from $20.1 million in Q1 2025. The company recorded a GAAP net loss of $8.3 million, or $0.03 per share, compared to a $1.44 loss per share in the prior-year period. It also provided full-year 2026 revenue guidance of $165–$175 million and highlighted a $48.1 million net cash gain from the sale of short-read sequencing assets. (Items: 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION, 9.01 FINANCIAL STATEMENTS AND EXHIBITS)
Tickers: $PACB